Nykredit A/S’s Quest Diagnostics DGX Stock Holding History

Nykredit A/S’s Portfolio DGX Stock Details DGX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$6M	Buy	+28,314	New	+$5.56M	0.02%	450

Other funds holding DGX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Boston Partners Boston, Massachusetts $113B AUM 38.87% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

EIG

EdgePoint Investment Group Toronto, Ontario, Canada $13.2B AUM 32.43% 1-Year Est. Return

Nykredit A/S's DGX Position: Q2 2026 in Review

Nykredit A/S opened a new position in Quest Diagnostics (DGX) in Q2 2026: 28,314 shares worth $6M. The stake represents 0.02% of the portfolio and ranks #450 among its holdings.

1,111 funds tracked by Wall St. Rank hold DGX as of Q2 2026.

Nykredit A/S held 28,314 shares of Quest Diagnostics worth $6M as of Q2 2026.
Quest Diagnostics was a new Nykredit A/S position in Q2 2026.
Quest Diagnostics made up 0.02% of Nykredit A/S's portfolio in Q2 2026, its #450 holding.
1,111 funds tracked by Wall St. Rank held Quest Diagnostics as of Q2 2026.

Based on Nykredit A/S's 13F filing for Q2 2026, filed 13 Aug 2026.